Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public access defibrillators

This article was originally published in The Gray Sheet

Executive Summary

HR 3462, the Community Access to Emergency Defibrillation Act of 2001 (Community AED Act) is introduced in the House Dec. 12 by Reps. Lois Capps (D-Calif.) and John Shimkus (R-Ill.). The bill authorizes more than $55 mil. a year for five years for communities to purchase automatic external defibrillators and to establish public access to defibrillation (PAD) programs. The measure is identical to S 1275, which was introduced July 31 by Sens. Edward Kennedy (D-Mass.) and Bill Frist (R-Tenn.). Staffers are cautiously optimistic that the bill could be hotlined for floor consideration in the next few weeks. AED manufacturer Medtronic VP-Corporate Controller Gary Ellis notes that its LifePak system direct-to-consumer advertising has helped to build awareness of the condition and its risk factors...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel